{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CASRegistryName","name":"288383-20-0"},{"type":"ChemicalStructureName","name":"4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline"},{"type":"CodeName","name":"AZ-D2171"},{"type":"CodeName","name":"AZD 2171"},{"type":"CodeName","name":"AZD2171"}],"definition":{"html":"An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","text":"An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types."},"drugInfoSummaryLink":null,"nciConceptId":"C80867","nciConceptName":"Cediranib","termId":818414,"name":"cediranib","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cediranib"},{"aliases":[{"type":"CodeName","name":"AZD2171"},{"type":"Synonym","name":"AZD2171 maleate"},{"type":"USBrandName","name":"Recentin"},{"type":"ForeignBrandName","name":"Recentin"},{"type":"ChemicalStructureName","name":"quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1- pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1)"},{"type":"ChemicalStructureName","name":"4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1- yl)propoxy]quinazoline (2Z)-but-2-enedioate"}],"definition":{"html":"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities.  Competing with adenosine triphosphate, cediranib  binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.","text":"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities.  Competing with adenosine triphosphate, cediranib  binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth."},"drugInfoSummaryLink":null,"nciConceptId":"C48379","nciConceptName":"Cediranib Maleate","termId":425596,"name":"cediranib maleate","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cediranib-maleate"}],"links":null}